New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

PCR Biosystems, a leading PCR reagent developer, has launched a new range of Bst polymerase reagents that offer greater sensitivity, speed, and specificity in all isothermal amplification applications. IsoFast™ Hot Start Bst Polymerase and associated ready mixes use proprietary AptaLock™ hot start technology to minimise non-specific amplification, leading to highly specific and sensitive results in as little as 30 minutes. A new colourimetric mix also enables analysts to detect results visually, vastly reducing equipment requirements. With these technologies, labs can now get reliable results more quickly, unlocking higher throughput testing.

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase. To avoid these issues, users must design primers carefully, and evaluate many more primer pairs for a single target than they would for standard PCR— both of which can be extremely time-consuming and complex.

To help alleviate these concerns, PCR Biosystems’ newly launched IsoFast™ reagents use AptaLock™, a reversible hot start technology that inhibits polymerase activity below 40 °C. As such, both non-specific amplification and primer dimer formation are minimised. Once the mixture is activated on heating, results can be obtained in as little as half an hour, allowing analysts to achieve highly sensitive, specific, and rapid detection of DNA targets. High-throughput testing is also possible, as reaction plates can be set up at room temperature without any issues.

What’s more, the colour mix contains a pH-based dye that changes colour when the desired target is amplified. As a result, the mix enables labs to visually identify positive or negative results without the need for plate readers or fluorometric PCR instruments. The mix is therefore particularly beneficial for regions where point-of-care or field-testing laboratories lack adequate facilities and instrumentation.

“Existing isothermal mixes present a number of challenges for organisations looking for sensitivity, specificity, and speed in DNA detection,” stated Alex Wilson, Co-founder and Business Development Manager, PCR Biosystems. “With our new mixes, labs get greatly improved specificity and sensitivity in their amplification reactions, so they obtain highly reliable results. Our internal studies show that they can be up to 50% faster than competitor mixes on tested targets too, which can make a critical difference for diagnostic and medical labs that need results quickly.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”